

REVIEW

The potential and challenges of alternative sources of β cells for the cure of type 1 diabetes

Monia Cito¹, Silvia Pellegrini¹, Lorenzo Piemonti^{1,2} and Valeria Sordi¹¹Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy²Vita-Salute San Raffaele University, Milan, ItalyCorrespondence should be addressed to V Sordi: sordi.valeria@hsr.it

Abstract

The experience in the field of islet transplantation shows that it is possible to replace β cells in a patient with type 1 diabetes (T1D), but this cell therapy is limited by the scarcity of organ donors and by the danger associated to the immunosuppressive drugs. Stem cell therapy is becoming a concrete opportunity to treat various diseases. In particular, for a disease like T1D, caused by the loss of a single specific cell type that does not need to be transplanted back in its originating site to perform its function, a stem cell-based cell replacement therapy seems to be the ideal cure. New and infinite sources of β cells are strongly required. In this review, we make an overview of the most promising and advanced β cell production strategies. Particular hope is placed in pluripotent stem cells (PSC), both embryonic (ESC) and induced pluripotent stem cells (iPSC). The first phase 1/2 clinical trials with ESC-derived pancreatic progenitor cells are ongoing in the United States and Canada, but a successful strategy for the use of PSC in patients with diabetes has still to overcome several important hurdles. Another promising strategy of generation of new β cells is the transdifferentiation of adult cells, both intra-pancreatic, such as alpha, exocrine and ductal cells or extra-pancreatic, in particular liver cells. Finally, new advances in gene editing technologies have given impetus to research on the production of human organs in chimeric animals and on *in situ* reprogramming of adult cells through *in vivo* target gene activation.

Key Words

- ▶ diabetes
- ▶ stem cells

Endocrine Connections
(2018) 7, R114–R125

Introduction

Type 1 diabetes (T1D) is an autoimmune disorder characterized by insulin-producing β cell death caused by autoreactive T cells (1). T1D contributes to 10% of the total 422 million diabetes cases worldwide. Although T1D is no more considered to be restricted to children and adolescents, it is one of the most common chronic diseases of childhood, and its incidence is constantly increasing; if incidence rates continue to increase on their existing path, global incidence could double over the next decade (for review see (2)).

Since 1922, exogenous insulin administration has been the most important lifesaving intervention for all T1D patients; however, chronic insulin treatment

is a double-edged sword since it fails to prevent long-term complications like ketoacidosis, kidney failure, cardiovascular diseases, neuropathy and retinopathy (3). The only possible definitive cure for this disease consists in providing a new β cell source capable of assessing blood sugar levels and secrete insulin in a glucose-dependent manner.

In the last 20 years, allogenic islets transplantation has been considered, in combination with a glucocorticoid-free immunosuppression, an unbeaten cell therapy approach for T1D patients reporting an excellent glucose control, improvement of chronic complications and quality of life (4). However, despite these promising

results, islets transplantation remains a limited therapy approach, due to the shortage of cadaveric donors, the variability of isolated human islets and the need for lifelong immunosuppression. Different approaches using stem cells to support islet survival and function are being explored in preclinical and clinical settings (5). Now, the most advanced strategies to solve these limitations are focused on embryonic/induced PSCs differentiation, reprogramming of adult somatic cells, and, more recently, generation of human organs with a chimera's approach and gene therapy to induce *in vivo* target gene activation (Fig. 1). This review describes the most important β cell replacement approaches that have been developed over the last decades focusing on their progresses, challenges and limits.

Unlimited pancreatic β cell source requirement fostered studies on differentiation of pluripotent stem cell (PSC) into functional insulin-secreting cells. Embryonic stem cells (ESC) and induced PSCs (iPSC) have been

eligible as new potential candidates to reach this goal due to their differentiation potential and their unlimited proliferation capacity maintaining an undifferentiated state (self-renewal) (6).

In 2006, Novocell (currently ViaCyte, Inc.) developed for the first time an efficient *in vitro* protocol to differentiate ESC into insulin-producing cells mimicking *in vivo* pancreatic organogenesis. Novocell's ESC-derived β cells yielded up to 7% insulin content but cells were not able to respond to glucose stimulation, essential properties of bona fide β cells, due to their functional immature state (7). Two years later, they reported a novel differentiation approach transplanting ESC-derived pancreatic endoderm cells into immunodeficient mice obtaining, after a 3-month period of spontaneous *in vivo* differentiation and maturation, glucose-responsive endocrine cells. In fact 3 months after implant, the levels of human insulin in the sera of mice were sufficient to fully protect mice against streptozotocin (STZ)-induced




Figure 1
Schematic representation of the most promising sources of pancreatic β cells.

hyperglycemia (8). These findings laid the groundwork for the first clinical trial in phase I/II started in 2014 (ClinicalTrials.gov identifier: NCT02239354) by ViaCyte. Shortly, human ESC-derived pancreatic progenitors (named PEC-01) were encapsulated into an immune-protecting medical device (named Encaptra drug delivery system) and transplanted in a small cohort of T1D patients. This trial aims to evaluate safety, long-term tolerability and efficacy of this system and the results are expected to be published soon.

Over the last 10 years, multiple variations have been made to the ViaCyte initial protocol in order to obtain an enrichment of pancreatic endocrine end products from differentiation of PSC *in vitro*. The most promising protocols were published in 2014 (9, 10) showing improvements in insulin secretion capacity of PSC-derived pancreatic cells. Rezanian and colleagues described a seven-stage *in vitro* differentiation protocol that led to efficient ESC conversion into glucose-responsive insulin-producing cells. Indeed, in a static *in vitro* glucose-stimulated insulin secretion, these cells showed an insulin secretion pattern close to human islets and reversed diabetes in two months after transplantation in STZ-induced diabetic mice (9). In parallel, Melton's group developed a different strategy using a three-dimensional cell culture system obtaining mature, mono-hormonal and functional stem cell-derived β cells. After only two weeks from transplantation, production of human insulin ameliorated hyperglycemia in NRG-Akita mice (10).

The main difference between these outstanding works consist indeed in the degree of maturation of the implanted cells and in the consequent timing of reversion of the disease: (i) ESC-derived pancreatic progenitor cells from ViaCyte require a 3-month period of *in vivo* maturation in mice to restore normoglycemia, (ii) mature pancreatic β cells from Rezanian and colleagues are able to secrete insulin only after a 40-day period of further maturation *in vivo*, while (iii) functional β cells from Melton's group ameliorated hyperglycemia after only two weeks. Whether it is better to transplant mature β cells or pancreatic progenitor cells capable of high efficiency *in vivo* differentiation is still under discussion and the results of ongoing clinical trials with pancreatic progenitor cells will provide an important point on this issue. Of course, the choice of cells at different stages of maturation has implications also on the safety issue, since it is assumed that cells at the stage of progenitors have a greater proliferative capacity and a certain degree of residual plasticity, which should drastically decrease in mature differentiated cells, making these last ones safer.

Despite these encouraging study results, several problems remain associated with the use of ESC: mainly the moral sensitivity regarding the use of human embryos for the production of ESC lines and the immune rejection of these cell lines by recipients in case of transplantation. To overcome these problems, in 2007, human pluripotent cells have been generated from somatic cells thanks to the world-renowned Yamanaka's reprogramming protocol (11). From then onward, in parallel with ESC, several protocols have been published to differentiate human iPSC derived from healthy or diabetic patients into pancreatic β cells with encouraging results (10, 12, 13, 14). This approach could lead to 'personalized' therapies preventing allogeneic graft rejection. Autologous PSCs could be obtained by generation of iPSC from somatic cells of subjects with T1D (15) or by transfer of somatic cell nuclei into oocytes that give rise to PSCs that are consistently equivalent to ESC (16, 17). PSCs obtained from both these technologies were shown to be able to efficiently differentiate into insulin-producing cells (12, 18). However, therapeutic approach using *in vitro* or *in vivo*-differentiated PSC is still a big question mark due to the possibility of tumor formation, secondary to residual anarchical undifferentiated cells at the last stage of pancreatic β cell differentiation (8, 19) and to the auto/alloimmune reaction against engrafted PSC-derived β cells.

In particular, safety of the final cell product remains a major issue to be considered to achieve a PSC-based transplantation therapy. Possible solutions include generation of safer iPSC lines, purification of the differentiated cells or cell encapsulation into medical devices. The most promising strategies at the moment are:

1. Non-viral and non-integrating gene delivery methods (transposons, protein transduction and RNA/miRNA transfection) for somatic cells reprogramming into PSC that decrease random transgene insertion into the host genome compared to previous retrovirus and lentivirus transduction (for review see (20)). With these strategies, it is possible to obtain iPSC without transgene integrations so as to avoid insertional mutagenesis, and residual expression and reactivation of reprogramming factors.
2. Identification of surface markers that allow the selection of the desired cell population or the deletion of unwanted cells like residual pluripotent cells. The first effort came from ViaCyte that identified CD142 (Tissue Factor) as a novel surface marker for the selection of pancreatic progenitor cells obtained through the

differentiation of ESC to increase purity; CD142⁺ cells transplanted *in vivo* give rise to all the pancreatic lineages, including functional insulin-producing cells (21). Other groups proposed alternative markers in the last years (22, 23), but the most recent and promising pancreatic progenitor cell surface marker identified is the pancreatic secretory granule membrane major glycoprotein 2 (GP2). GP2 is expressed in combination with NKX6.1 and PTF1 α , key transcription factors in pancreas development, and it was demonstrated that hPSC-derived GP2⁺ cells, differentiated in pancreatic progenitors expressing high levels of NKX6.1, generate β -like cells more efficiently compared to the GP2-negative fraction (24, 25). In addition, depletion of pluripotent cells from differentiated PSC cultures using genetic, chemical and antibody-based approaches has been investigated as promising approach to increase safety of PSC differentiated cells. For instance, Lee and coworkers discovered that chemical inhibitors of survivin (like quercetin or YM155) induced selective and complete cell death of undifferentiated hPSC (26), while Ben-David and colleagues using a high-throughput screen of over 52,000 small molecules identified an inhibitor of stearyl-coA desaturase (SCD1) able to selectively eliminate hPSC (27). Over the latest years, photodynamic approach is getting a foothold. Interestingly, it was demonstrated that CDy1, a PSC-selective fluorescent probe, led to mitochondrial ROS production upon visible light irradiation and consequent selective PSC death, avoiding teratoma formation (28). An additional approach is the introduction of a suicide gene under *NANOG* promoter control leading to selective removal of undifferentiated PSCs from differentiated cell culture after drug treatment (29). Moreover, also the introduction of an innovative inducible caspase-9 suicide gene in hPSC able to induced 94–99% cell death after chemical inducer of dimerization (CID) treatment has been tested (30).

3. Development of macro-encapsulation devices able to protect cells from immune attack and allow retrieval in case of undesirable tumor. During the past decade, much effort has been directed to the clinical application of therapeutic cells encapsulation in biocompatible, permselective and safe macrodevices (31). Beta-O2 developed an alginate scaffold containing allogenic human islets supplied with oxygen by daily injection, known as β Air device (32). The first T1D patient was implanted in 2012 in the absence of immunosuppression and

showed persistent graft function with preservation of islets morphology although only moderate improvements on clinical disease were observed (33). Two years later, Beta-O2 Technologies started a clinical trial (NCT02064309) to evaluate safety and efficacy of human islet encapsulation into β Air device in T1D patients. Moreover, also the ability of β Air technology to sustain hESC differentiation into mature endocrine cells in rodent was demonstrated (34). Recently, Beta-O2 bioartificial pancreas device was used as preclinical model for xenogenic islet transplantation. Authors reported enduring graft function, resulting in regulated insulin secretion, without generation of immune system attack (35). The main limitations of this device consist in the partial function of encapsulated islets and in the procedure of daily exogenous oxygen refilling, which requires a knowledgeable and compliant patient.

As previously mentioned, in 2014, ViaCyte launched the first phase I/II human clinical trial evaluating efficiency of Encaptra Device combined with PEC-01 cells in T1D patients. Additionally, in 2017, U.S. Food and Drug Administration (FDA) has allowed clinical testing for ViaCyte's PEC-Direct product, a new open Encaptra Device allowing direct vascularization of PEC-01 cells. At the 5th Annual European Advanced Therapies Investor day (<http://eu.arminvestorday.com>), ViaCyte presented some data of the ongoing clinical trial reporting good tissue integration and vascularization of the system in two patients. Another device received approval from the FDA for phase I/II clinical study in T1D patients in US: the Cell Pouch System is a medical biocompatible macrodevice designed to be implanted in the subcutaneous site, forming highly vascularized tissue chambers few weeks prior to transplantation of islets (36). Ongoing clinical trials from ViaCyte are summarized in Table 1.

β cells from direct differentiation

As discussed, clinical application of PSCs is not without roadblocks due to shortage of genetic understanding of pancreatic embryogenesis leading to partial β cell differentiation efficiency, risk of tumor formation caused by residual undifferentiated cells and the eventuality of cell death after transplantation. Thus, several research groups focused on direct reprogramming (transdifferentiation) of non- β adult cells, such as pancreatic exocrine cells, liver cells and stomach cells, into insulin-producing cells,

Table 1 Clinical studies of ViaCyte testing safety, tolerability and efficacy of ESC-derived pancreatic progenitor cells (PEC-01 cells) encapsulated into a macrodevice (Encaptra cell delivery system).

ClinicalTrials.gov identifier	Name	Cell product	Study type	Study location	Conditions	Status
NCT02239354	A safety, tolerability and efficacy study of VC-01 combination product in subjects with type 1 diabetes mellitus	VC-01 combination product (PEC-Encap)	Phase 1/2	University of California at San Diego, United States University of Alberta Hospital, Canada	Type 1 diabetes mellitus, no immunosuppression	Active, not recruiting
NCT03162926	A safety and tolerability study of VC-02 combination product in subjects with type 1 diabetes mellitus	VC-02 combination product (PEC-Direct)	Phase 1	University of Alberta, Edmonton, Canada	Type 1 diabetes mellitus, with immunosuppression	Active, not recruiting
NCT03163511	A safety, tolerability and efficacy study of VC-02 combination product in subjects with type 1 diabetes mellitus and hypoglycemia unawareness	VC-02 combination product (PEC-Direct)	Phase 1/2	University of California, San Diego, United States University of Minnesota, Minneapolis, United States Ohio State University, Columbus, United States University of Alberta, Edmonton, Canada University of British Columbia, Vancouver, Canada	Type 1 diabetes mellitus with hypoglycemia, with immunosuppression	Active, recruiting

skipping the pluripotent stage (37, 38, 39). Common endodermic origin of these cell types suggests that they could be converted into insulin-producing β cells.

Alpha-to- β

Under different diabetic stress conditions, glucagon-producing α cells are important to maintain β cell health and function through GLP-1 secretion (40, 41) suggesting an α -cell-mediated adaptive response to β -cell stress and injury. Collombat and colleagues demonstrated that overexpression of ectopic Paired Box 4 (*PAX4*) (42) or selective inhibition of Aristaless-Related Homeobox (*ARX*) (43) are able to determine an α cells conversion into functional β cells and restore normoglycemia in STZ-induced diabetic mice. Moreover, Herrera's group showed that a diphtheria toxin-mediated β -cell removal (>99%)

in mice led to an α cells expansion and a spontaneous reprogramming in β cells (44). Thus, over the latest years, the possibility to induce direct differentiation of glucagon-producing α cells into insulin-producing β cells have captured attention of diabetes researchers as interesting therapeutic approach for restoring β cell function in T1D patients. Recently, Collombat's group provided *in vitro* and *ex vivo* experimental evidences that long-term γ -aminobutyric acid (GABA) administration, a food supplement, can induce human α -cell-mediated β -like cell neogenesis opening the way for clinical trials with GABA compounds (45). Additionally, Li and colleagues corroborated GABA data identifying a small antimalarial molecule, named Artemisinins, involved in *ARX* repression and consequent increased GABA signaling. This mechanism resulted in decreased glucagon secretion by α cells and their differentiation into insulin-producing cells (46). However, in the same

year, another group confirmed the inhibition of *ARX* after Artemether treatment (an Artemisinins derivative) but no α to β conversion in mouse primary islets (47). These controversial findings generated a state of uncertainty regarding GABA transdifferentiation effects. Very recently, the transcription factors *PDX1* and *MAF-A* were delivered *in vivo* with adeno-associated virus to the mouse pancreas through the pancreatic duct to reprogram α cells into functional β cells. Blood glucose levels normalized in both chemically induced diabetic mice and autoimmune non-obese diabetic (NOD) mice. This gene therapy strategy also induced α to β cell conversion in toxin-treated human islets, which restored blood glucose levels in NOD/SCID mice upon transplantation (48).

Exocrine-to- β

Exocrine pancreas, consisting of acinar and ductal cells, makes up approximately 98 percent of the adult organ (49), therefore, much attention was focused on the possibility to generate new β cells from these cell types.

Acinar cells

Melton's group provided evidence about acinar-to- β transdifferentiation inducing *in vivo* overexpression of three key β -cell transcription factors *PDX1*, *NGN3* and *MAFA* in combination with GFP in mice. By 72 h after viral infection in *Rag1*^{-/-} non-diabetic animals, new GFP-insulin-positive cells were detected. After 10 days, GFP-positive cells presented key features of bona fide β cells. Furthermore, overexpression of transcription factors in STZ-induced diabetic mice led to a significant decrease of hyperglycemia, although did not reverse diabetes (50). Lately, they confirmed the survival and function of lineage-reprogrammed cells *in vivo* up to 1 year (51). Similarly, Docherty's group described a new acinar-to- β reprogramming protocol, starting from *in vitro* cultured primary human exocrine cells. Epithelial-to-mesenchymal transition (EMT) inhibition maintained acinar exocrine phenotype in culture and overexpression of the four pancreatic transcription factors *PDX1*, *NGN3*, *PAX4* and *MAFA*, with a combination of several growth factors, generated functional glucose-responding insulin-producing cells, that were able to normalize glycemia in STZ-induced diabetic immunodeficient mice (52). In 2016, the same group confirmed the possibility to generate functional clinically relevant β cells from human exocrine pancreas, adding *ARX* knockdown to the strategy (53).

In the latest years, a Belgian group demonstrated that forcing expression of mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription 3 (STAT3) in human exocrine cells cultured in 3D structures induces *NGN3* expression, leading to an acinoinsular functional reprogramming (54). Obviously, these approaches present clinical limitation due to the use of viral vectors. For this reason, several researchers focused on pharmacological induction of transdifferentiation. For instance, epidermal growth factor (EGF), nicotinamide, leukemia inhibitory factor (LIF) or ciliary neurotrophic factor (CNTF) combination reprogrammed rat acinar cells into insulin-producing β cells *in vitro* able to restore normoglycemia in diabetic mice. Molecular study reported the involvement of CNTF in STAT3 signaling pathway activation leading to reactivation of *NGN3* expression in adult acinar cells forcing differentiation into β cells (55, 56). Recently, a Japanese group showed that inducing ectopic expression of glucagon-like peptide-1 receptor (GLP1R) combined with gastrin and exendin-4 also, synergistically promoted β cell reprogramming of acinar cells (57).

Duct cells

Reprogramming of ductal cells into β cells is one of the most controversial issue in the field. In the last two decades, several papers showed budding of β cells from duct cells speculating that pancreatic duct could be a potential stem cell niche for insulin-producing cells (58). In 2008, Heimberg's group reported that after pancreatic duct ligation (PDL) in mice, β cell progenitors located in the duct could re-express *NGN3* and differentiate into glucose-responsive β cells (59). In the same year, another group corroborated these findings showing, through the forced expression of ductal marker carbonic anhydrase II (CAII), that duct cells acted as β cell progenitors after birth or PDL, leading to the formation of new islets (60). Intriguingly, Corritore, in collaboration with our group, forced purified human ductal cells to undergo an EMT and proliferate. After expansion, it was possible to differentiate, with a protocol mimicking pancreatic development, duct-derived cells into β -cells. These cells expressed β cell markers and were able to secrete insulin, but not in a glucose-dependent manner (61). More recently, Zhang and colleagues provided evidence that long-term administration of gastrin and EGFs *in vivo* in diabetic mice, resulted in ductal cell transdifferentiation into new β cells and consequent diabetes reversion (62). However, these findings are still subject of dispute since several studies suggested a non-ductal contribution to endocrine cell

regeneration (63, 64, 65, 66). These conflicting findings generate doubts regarding the importance of ductal cells in β cell regeneration.

Liver-to- β

Pancreas, gastrointestinal tract and liver have the same embryonic origin deriving from primitive foregut endoderm; thus, a transdifferentiation between them is conceivable.

Liver is the largest organ in the body and, unlike β cells, is able to regenerate and proliferate efficiently. In addition, liver shares with pancreas the glucose responsiveness. Thus, hepatic cells represent a good therapeutic potential candidate for β cell generation (67, 68). Ferber and colleagues were the first researchers demonstrating that *in vivo* adenoviral-mediated ectopic expression of *PDX1* in liver generated increase of silent endogenous *INS* gene expression. Moreover, insulin levels derived from hepatic-*PDX1* overexpression ameliorated STZ-induced diabetes (69, 70, 71). From 2000 onwards, several authors have provided evidence of liver-to- β transdifferentiation through hepatic ectopic expression of pancreatic transcription factors, such as *PDX1*, *NGN3*, *MAFA* and *NKX6.1*, leading to a partial β cell phenotype and reversion of hyperglycemia in chemical-induced diabetic mice, indicating this approach as a promising cell-based replacement therapy for diabetes (72, 73, 74, 75).

Gastrointestinal-to- β

Gastrointestinal tissues, composed by stomach and intestine, harbor *NGN3*-expressing progenitor cells able to become hormone-producing cells (76). Over the last decade, several evidences have demonstrated that gastrointestinal cells can be reprogrammed into insulin-producing cells through expression or deletion of some transcription factors. Recent studies showed that intestinal cells gave rise to functional β -like cells by endocrine-specific ablation of Forkhead box protein O1 (*FOXO1*) transcription factor (77, 78). In 2014, Chen and coworkers reported a rapid conversion of intestinal crypt cells into endocrine cells through ectopic expression of *PDX1*, *MAFA* and *NGN3* factors. They observed formation of 'neoislets' below the crypt base that were able to secrete insulin in a glucose-dependent manner and ameliorate hyperglycemia in diabetic mice (79). Recently, Zhou's

group showed that antral enteroendocrine cells also were able to generate functional insulin-positive cells through adenoviral expression of the same transcription factors. This approach resulted in higher transdifferentiation efficiency compared to the previously mentioned intestinal enteroendocrine cell reprogramming. Intriguingly, authors assembled *in vitro* reprogrammed antral stomach cells into bio-organoids and observed hyperglycemia reversion in diabetic mice. This novel approach shed light to engineered stomach tissue as renewable functional β cell source (37).

Last advances in the field: genome editing

Finally, advances in genome editing technologies have revolutionized the field. In particular, discovery of the bacterial immune system CRISPR/Cas9 has led to the development of tools for rapid and efficient RNA-based, sequence-specific genome editing (80). Furthermore, novel modifications to the CRISPR/Cas9 system have provided opportunities for regulating gene expression and for creating epigenetic alterations, without creating DNA breaks (81). Very recently, a new system for *in vivo* activation of endogenous target genes through trans-epigenetic remodeling was reported: this system relies on recruitment of Cas9 and transcriptional activation complexes to target loci by modified single guide RNAs, and it was used to transdifferentiate liver cells into insulin-positive cells, acting on *PDX1* levels in mice. Besides, when mice, rendered diabetic with streptozotocin (STZ) treatment, were treated with the system for endogenous insulin gene activation, they partially rescued hyperglycemia (82).

Last advances in the field: chimeric organs

The availability of PSCs boosted the possibility of producing human organs in animals. The main strategy to obtain chimeric animals was based on blastocyst complementation: mouse ESC injected into a blastocyst were shown able to contribute to embryo development (83). When blastocyst and ESC had a different genetic background, the outcome was a chimeric mouse with cells of both origins in its organs. Genetically modified PSCs injected in blastocyst are the basis of the production of transgenic mice. More recently, blastocyst complementation was used to generate interspecies chimeric animals. The hypothesis was that if PSC were

injected into blastocysts obtained from mutant mice in which the development of a certain organ was precluded by genetic manipulation, thereby leaving a niche for organ development, the PSC-derived cells would developmentally compensate for the defect and form the missing organ. At first, rat pancreas was generated by injection of PSC into pancreas-deficient *PDX1*^{-/-} mouse blastocysts (84), then kidney was generated using *SALL1*^{-/-} mouse blastocysts (85). The demonstration that a rat organ can be produced in a mouse suggested that it could be possible to produce xenogeneic organs in various animal species, including production of human organs. This could have a tremendous impact in the field of regenerative medicine, since the shortage of donor organs is a major obstacle to the expansion of whole organ replacement therapies. For production of human organs, human iPSC would be injected into blastocysts obtained from carrier animals genetically modified in order to block the development of a given organ. Thus, only human cells would contribute to the development of that organ (86). Importantly, also in this case, the use of autologous iPSC could allow the production of autologous human organs and therefore ideally reduce the long-term need for immunosuppressive drugs after transplantation. These chimeric animals would be raised until the human organ reached the required size and then they would be killed for transplantation. Pigs are the most attractive animals to bear human organs for various reasons: (i) the size of their organs is similar, (ii) their metabolism (for instance, diet and temperature) is close to the human one, (iii) there is a significant experience regarding pig cell transplantation in humans within the context of xenotransplantation trials, which facilitates the identification of hazards and barriers, such as infectious and immunological risks, to be overcome for transplantation in humans of human cells or organs that have been grown in a pig (87).

Some preliminary experiments have already been performed, such as injection of human ESC into a mouse blastocyst (88), but the results obtained suggest that this process is rather inefficient (89). At the beginning of 2017, two seminal papers were published regarding the creation of chimeras using pluripotent human stem cells obtained from iPSC and blastocysts of pigs and bovine (90, 91). In Belmonte's paper *PDX1* gene, fundamental for pancreas development, was initially suppressed by CRISPR-Cas9-mediated gene editing in the mouse zygote creating a blastocyst not able to give life to adult mice with pancreas, then rat stem cells were inserted into the blastocyst and the resulting embryo gave rise to adult mice with pancreas composed exclusively of rat cells. The same

type of approach was also successfully applied with other targets such as *NKX2.5* (relevant for cardiac development) and *PAX6* (relevant for eye development) demonstrating that the approach can be extended in a systematic way. Finally, the authors applied the same strategy using human stem cells in pig or bovine blastocysts. Although with less efficiency than the rat-mouse model, the possibility of obtaining chimeric human embryos was demonstrated (91). In Nakauchi's paper, mouse PSCs were injected into *PDX1*-deficient rat blastocysts, and rat-sized pancreas composed of mouse-PSC-derived cells were generated. Islets isolated from the mouse-rat chimeric pancreas were transplanted into diabetic mice and were able to normalize and maintain host blood glucose levels for over 1 year in the absence of immunosuppression (90). Finally, a new study reported the possibility to disable pancreas development in sheep through CRISPR/Cas9 microinjection in oocytes, widening the possibility to create human-animal chimeras for human pancreas generation (92).

These works constitute a turning point in the field of regenerative medicine, opening up unimaginable horizons, but also impose big challenges. From the biotechnological point of view, the proof of principle has been developed but efficiency of human-pig chimeras is low and the insertion of human cells into the pig embryo has shown important limitations. The field of human chimeras also raises strong ethical issues. The main ethical dilemmas are whether the chimera can be killed in order to obtain organs and if a man-animal chimera has a different ethical identity than the animal one. Finally, there is obviously an enormous ethical concern in the case of any human germ cell contribution. Overall, this is an exciting but extremely delicate field of research.

Future perspectives

In conclusion, β cells derived from PSC currently represent the most concrete new source for cell replacement therapy in T1D. The results of ongoing clinical trials will provide valuable information and will tell us if this is the strategy of the future. Looking ahead, the field of cell therapy with iPSC is facing a turning point, where new technologies and synergies can transform a type of approach limited to few patients into a therapeutic option for large groups of patients. This evolution is closely linked to the scale up of cell reprogramming, differentiation and banking, which is necessarily connected to the industrialization of processes. In the meantime, the huge progresses made by

technologies of *ex vivo* and *in vivo* gene editing allowed increasingly efficient transformation of somatic cells into β cells and the creation of new chimeric organs. These approaches have the potential to innovate the field, but issues of safety and ethics will need to be considered.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

The work of the authors is currently supported by the European Commission (H2020 grant 681070), Fondazione Diabete Ricerca ONLUS (Società Italiana di Diabetologia-SID) and Eli Lilly Italia (grant 'Sostegno alla ricerca sul diabete 2017').

References

- Atkinson MA, Bluestone JA, Eisenbarth GS, Hebrok M, Herold KC, Accili D, Pietropaolo M, Arvan PR, Von Herrath M, Markel DS, *et al.* How does type 1 diabetes develop? The notion of homicide or -cell suicide revisited. *Diabetes* 2011 **60** 1370–1379. (<https://doi.org/10.2337/db10-1797>)
- Atkinson MA, Eisenbarth GS & Michels AW. Type 1 diabetes. *Lancet* 2014 **383** 69–82. ([https://doi.org/10.1016/S0140-6736\(13\)60591-7](https://doi.org/10.1016/S0140-6736(13)60591-7))
- Van Belle TL, Coppieters KT & von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. *Physiological Reviews* 2011 **91** 79–118. (<https://doi.org/10.1152/physrev.00003.2010>)
- Maffi P & Secchi A. Clinical results of islet transplantation. *Pharmacological Research* 2015 **98** 86–91. (<https://doi.org/10.1016/j.phrs.2015.04.010>)
- Sordi V, Pellegrini S, Krampera M, Marchetti P, Pessina A, Ciardelli G, Fadini G, Pintus C, Pantè G & Piemonti L. Stem cells to restore insulin production and cure diabetes. *Nutrition, Metabolism and Cardiovascular Diseases* 2016 **27** 583–600. (<https://doi.org/10.1016/j.numecd.2017.02.004>)
- Lysy PA, Weir GC & Bonner-Weir S. Concise review: pancreas regeneration: recent advances and perspectives. *Stem Cells Translational Medicine* 2012 **1** 150–159. (<https://doi.org/10.5966/sctm.2011-0025>)
- D'Amour KA, Bang AG, Eliazar S, Kelly OG, Agulnick AD, Smart NG, Moonman MA, Kroon E, Carpenter MK & Baetge EE. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. *Nature Biotechnology* 2006 **24** 1392–1401. (<https://doi.org/10.1038/nbt1259>)
- Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazar S, Young H, Richardson M, Smart NG, Cunningham J, *et al.* Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. *Nature Biotechnology* 2008 **26** 443–452. (<https://doi.org/10.1038/nbt1393>)
- Rezania A, Bruin JE, Arora P, Rubin A, Batushansky I, Asadi A, O'Dwyer S, Quiskamp N, Mojibian M, Albrecht T, *et al.* Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. *Nature Biotechnology* 2014 **32** 1121–1133. (<https://doi.org/10.1038/nbt.3033>)
- Pagliuca FW, Millman JR, Gürtler M, Segel M, Van Dervort A, Ryu JH, Peterson QP, Greiner D & Melton DA. Generation of functional human pancreatic β cells in vitro. *Cell* 2014 **159** 428–439. (<https://doi.org/10.1016/j.cell.2014.09.040>)
- Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K & Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 2007 **131** 861–872. (<https://doi.org/10.1016/j.cell.2007.11.019>)
- Millman JR, Xie C, Dervort Van A, Gürtler M, Pagliuca FW & Melton DA. Generation of stem cell-derived β -cells from patients with type 1 diabetes. *Nature Communications* 2016 **7** 11463. (<https://doi.org/10.1038/ncomms11463>)
- Kondo Y, Toyoda T, Ito R, Funato M, Hosokawa Y, Matsui S, Sudo T, Nakamura M, Okada C, Zhuang X, *et al.* Identification of a small molecule that facilitates the differentiation of human iPSCs/ESCs and mouse embryonic pancreatic explants into pancreatic endocrine cells. *Diabetologia* 2017 **60** 1454–1466. (<https://doi.org/10.1007/s00125-017-4302-7>)
- Yabe SG, Fukuda S, Takeda F, Nashiro K, Shimoda M & Okochi H. Efficient generation of functional pancreatic β -cells from human induced pluripotent stem cells. *Journal of Diabetes* 2017 **9** 168–179. (<https://doi.org/10.1111/1753-0407.12400>)
- Maehr R, Chen S, Snitow M, Ludwig T, Yagasaki L, Goland R, Leibel RL & Melton DA. Generation of pluripotent stem cells from patients with type 1 diabetes. *PNAS* 2009 **106** 15768–15773. (<https://doi.org/10.1073/pnas.0906894106>)
- Wakayama S, Jakt ML, Suzuki M, Araki R, Hikichi T, Kishigami S, Ohta H, Van Thuan N, Mizutani E, Sakaide Y, *et al.* Equivalency of nuclear transfer-derived embryonic stem cells to those derived from fertilized mouse blastocysts. *Stem Cells* 2006 **24** 2023–2033. (<https://doi.org/10.1634/stemcells.2005-0537>)
- Yamada M, Johannesson B, Sagi I, Burnett LC, Kort DH, Prosser RW, Paull D, Nestor MW, Freeby M, Greenberg E, *et al.* Human oocytes reprogram adult somatic nuclei of a type 1 diabetic to diploid pluripotent stem cells. *Nature* 2014 **510** 533–536. (<https://doi.org/10.1038/nature13287>)
- Sui L, Danzl N, Campbell SR, Viola R, Williams D, Xing Y, Wang Y, Phillips N, Poffenberger G, Johannesson B, *et al.* β -Cell replacement in mice using human type 1 diabetes nuclear transfer embryonic stem cells. *Diabetes* 2018 **67** 26–35. (<https://doi.org/10.2337/db17-0120>)
- Rezania A, Bruin JE, Riedel MJ, Mojibian M, Asadi A, Xu J, Gauvin R, Narayan K, Karanu F, O'Neil JJ, *et al.* Maturation of human embryonic stem cell-derived pancreatic progenitors into functional islets capable of treating pre-existing diabetes in mice. *Diabetes* 2012 **61** 2016–2029. (<https://doi.org/10.2337/db11-1711>)
- Hu K. All roads lead to induced pluripotent stem cells: the technologies of iPSC generation. *Stem Cells and Development* 2014 **23** 1285–1300. (<https://doi.org/10.1089/scd.2013.0620>)
- Kelly OG, Chan MY, Martinson LA, Kadoya K, Ostertag TM, Ross KG, Richardson M, Carpenter MK, D'Amour KA, Kroon E, *et al.* Cell-surface markers for the isolation of pancreatic cell types derived from human embryonic stem cells. *Nature Biotechnology* 2011 **29** 750–756. (<https://doi.org/10.1038/nbt.1931>)
- Jiang W, Sui X, Zhang D, Liu M, Ding M, Shi Y & Deng H. CD24: a novel surface marker for PDX1-positive pancreatic progenitors derived from human embryonic stem cells. *Stem Cells* 2011 **29** 609–617. (<https://doi.org/10.1002/stem.608>)
- Hald J, Galbo T, Rescan C, Radzikowski L, Sprinkel AE, Heimberg H, Ahnfelt-Rønne J, Jensen J, Scharfmann R, Gradwohl G, *et al.* Pancreatic islet and progenitor cell surface markers with cell sorting potential. *Diabetologia* 2012 **55** 154–165. (<https://doi.org/10.1007/s00125-011-2295-1>)
- Ameri J, Borup R, Prawiro C, Ramond C, Schachter KA, Scharfmann R & Semb H. Efficient generation of glucose-responsive beta cells from isolated GP2+ human pancreatic progenitors. *Cell Reports* 2017 **19** 36–49. (<https://doi.org/10.1016/j.celrep.2017.03.032>)
- Cogger KE, Sinha A, Sarangi F, McGaugh EC, Saunders D, Dorrell C, Mejia-Guerrero S, Aghazadeh Y, Rourke JL, Sreaton RA, *et al.* Glycoprotein 2 is a specific cell surface marker of human pancreatic progenitors. *Nature Communications* 2017 **8** 331. (<https://doi.org/10.1038/s41467-017-00561-0>)

- 26 Lee M-O, Moon SH, Jeong H-C, Yi JY, Lee TH, Shim SH, Rhee YH, Lee SH, Oh SJ, Lee MY, *et al.* Inhibition of pluripotent stem cell-derived teratoma formation by small molecules. *PNAS* 2013 **110** E3281–E3290. (<https://doi.org/10.1073/pnas.1303669110>)
- 27 Ben-David U, Gan Q-F, Golan-Lev T, Arora P, Yanuka O, Oren YS, Leikin-Frenkel A, Graf M, Garippa R, Boehringer M, *et al.* Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. *Cell Stem Cell* 2013 **12** 167–179. (<https://doi.org/10.1016/j.stem.2012.11.015>)
- 28 Cho S-J, Kim S-Y, Park S-J, Song N, Kwon H-Y, Kang N-Y, Moon S-H, Chang Y-T & Cha H-J. Photodynamic approach for teratoma-free pluripotent stem cell therapy using CDy1 and visible light. *ACS Central Science* 2016 **2** 604–607. (<https://doi.org/10.1021/acscentsci.6b00099>)
- 29 Chen F, Cai B, Gao Y, Yuan X, Cheng F, Wang T, Jiang M, Zhou Y, Lahn BT, Li W, *et al.* Suicide gene-mediated ablation of tumor-initiating mouse pluripotent stem cells. *Biomaterials* 2013 **34** 1701–1711. (<https://doi.org/10.1016/j.biomaterials.2012.11.018>)
- 30 Yagyu S, Hoyos V, Del Bufalo F & Brenner MK. An inducible caspase-9 suicide gene to improve the safety of therapy using human induced pluripotent stem cells. *Molecular Therapy* 2015 **23** 1475–1485. (<https://doi.org/10.1038/mt.2015.100>)
- 31 Scharp DW & Marchetti P. Encapsulated islets for diabetes therapy: history, current progress, and critical issues requiring solution. *Advanced Drug Delivery Reviews* 2014 **67–68** 35–73. (<https://doi.org/10.1016/j.addr.2013.07.018>)
- 32 Ludwig B, Zimerman B, Steffen A, Yavriants K, Azarov D, Reichel A, Vardi P, German T, Shabtay N, Rotem A, *et al.* A novel device for islet transplantation providing immune protection and oxygen supply. *Hormone and Metabolic Research* 2010 **42** 918–922. (<https://doi.org/10.1055/s-0030-1267916>)
- 33 Ludwig B, Reichel A, Steffen A, Zimerman B, Schally AV, Block NL, Colton CK, Ludwig S, Kersting S, Bonifacio E, *et al.* Transplantation of human islets without immunosuppression. *PNAS* 2013 **110** 19054–19058. (<https://doi.org/10.1073/pnas.1317561110>)
- 34 Bukys MA, Bakos B, Afelik S, Zimmerman B, Barbaro B, Lin DL, Vaca P, Goldman T, Rotem A, Damaser M, *et al.* Xenotransplantation of macro-encapsulated human islet and pluripotent stem cell-derived pancreatic progenitors in absence of immunosuppression. *Diabetes* 2014 **2** 1–10. (<https://doi.org/10.19104/jorm.2017.109>)
- 35 Ludwig B, Ludwig S, Steffen A, Knauf Y, Zimerman B, Heinke S, Lehmann S, Schubert U, Schmid J, Bleyer M, *et al.* Favorable outcome of experimental islet xenotransplantation without immunosuppression in a nonhuman primate model of diabetes. *PNAS* 2017 **114** 11745–11750. (<https://doi.org/10.1073/pnas.1708420114>)
- 36 Pepper AR, Pawlick R, Gala-Lopez B, MacGillivray A, Mazzuca DM, White DJG, Toleikis PM & Shapiro AMJ. Diabetes is reversed in a murine model by marginal mass syngeneic islet transplantation using a subcutaneous cell pouch device. *Transplantation* 2015 **99** 2294–2300. (<https://doi.org/10.1097/TP.0000000000000864>)
- 37 Ariyachet C, Tovaglieri A, Xiang G, Lu J, Shah MS, Richmond CA, Verbeke C, Melton DA, Stanger BZ, Mooney D, *et al.* Reprogrammed stomach tissue as a renewable source of functional β cells for blood glucose regulation. *Cell Stem Cell* 2016 **18** 410–421. (<https://doi.org/10.1016/j.stem.2016.01.003>)
- 38 Sisakhtnezhad S & Matin MM. Transdifferentiation: a cell and molecular reprogramming process. *Cell and Tissue Research* 2012 **348** 379–396. (<https://doi.org/10.1007/s00441-012-1403-y>)
- 39 Lysy PA, Weir GC & Bonner-Weir S. Making β cells from adult cells within the pancreas. *Current Diabetes Reports* 2013 **13** 695–703. (<https://doi.org/10.1007/s11892-013-0400-1>)
- 40 Kilimnik G, Kim A, Steiner DF, Friedman TC & Hara M. Intra-islet production of GLP-1 by activation of prohormone convertase 1/3 in pancreatic α -cells in mouse models of β -cell regeneration. *Islets* 2010 **2** 149–155. (<https://doi.org/10.4161/isl.2.3.11396>)
- 41 Liu Z, Stanojevic V, Avadhani S, Yano T & Habener JF. Stromal cell-derived factor-1 (SDF-1)/chemokine (C-X-C motif) receptor 4 (CXCR4) axis activation induces intra-islet glucagon-like peptide-1 (GLP-1) production and enhances beta cell survival. *Diabetologia* 2011 **54** 2067–2076. (<https://doi.org/10.1007/s00125-011-2181-x>)
- 42 Collombat P, Xu X, Ravassard P, Sosa-Pineda B, Dussaud S, Billestrup N, Madsen OD, Serup P, Heimberg H & Mansouri A. The ectopic expression of Pax4 in the mouse pancreas converts progenitor cells into alpha and subsequently beta cells. *Cell* 2009 **138** 449–462. (<https://doi.org/10.1016/j.cell.2009.05.035>)
- 43 Courtney M, Gjernes E, Druelle N, Ravaud C, Vieira A, Ben-Othman N, Pfeifer A, Avolio F, Leuckx G, Lacas-Gervais S, *et al.* The inactivation of Arx in pancreatic α -cells triggers their neogenesis and conversion into functional β -like cells. *PLoS Genetics* 2013 **9** e1003934. (<https://doi.org/10.1371/journal.pgen.1003934>)
- 44 Thorel F, Népote V, Avril I, Kohno K, Desgraz R, Chera S & Herrera PL. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. *Nature* 2010 **464** 1149–1154. (<https://doi.org/10.1038/nature08894>)
- 45 Ben-Othman N, Vieira A, Courtney M, Record F, Gjernes E, Avolio F, Hadzic B, Druelle N, Napolitano T, Navarro-Sanz S, *et al.* Long-term GABA administration induces alpha cell-mediated beta-like cell neogenesis. *Cell* 2017 **168** 73.e11–85.e11. (<https://doi.org/10.1016/j.cell.2016.11.002>)
- 46 Li J, Casteels T, Frogne T, Ingvorsen C, Honoré C, Courtney M, Huber KVM, Schmitner N, Kimmel RA, Romanov RA, *et al.* Artemisinins target GABA a receptor signaling and impair α cell identity. *Cell* 2017 **168** 86.e15–100.e15. (<https://doi.org/10.1016/j.cell.2016.11.010>)
- 47 Van der Meulen T, Lee S, Noordeloos E, Donaldson CJ, Adams MW, Noguchi GM, Mawla AM & Huisin MO. Artemether does not turn α cells into β cells. *Cell Metabolism* 2017 **27** 218.e4–225.e4. (<https://doi.org/10.1016/j.cmet.2017.10.002>)
- 48 Xiao X, Guo P, Shiota C, Zhang T, Coudriet GM, Fischbach S, Prasad K, Fusco J, Ramachandran S, Witkowski P, *et al.* Endogenous reprogramming of alpha cells into beta cells, induced by viral gene therapy, reverses autoimmune diabetes. *Cell Stem Cell* 2018 **22** 78. e4–90.e4. (<https://doi.org/10.1016/j.stem.2017.11.020>)
- 49 Guney MA & Gannon M. Pancreas cell fate. *Birth Defects Research, Part C: Embryo Today, Reviews* 2009 **87** 232–248. (<https://doi.org/10.1002/bdrc.20156>)
- 50 Zhou Q, Brown J, Kanarek A, Rajagopal J & Melton DA. In vivo reprogramming of adult pancreatic exocrine cells to β -cells. *Nature* 2008 **455** 627–632. (<https://doi.org/10.1038/nature07314>)
- 51 Li W, Cavelti-Weder C, Zhang Y, Clement K, Donovan S, Gonzalez G, Zhu J, Stemann M, Xu K, Hashimoto T, *et al.* Long-term persistence and development of induced pancreatic beta cells generated by lineage conversion of acinar cells. *Nature Biotechnology* 2014 **32** 1223–1230. (<https://doi.org/10.1038/nbt.3082>)
- 52 Lima MJ, Muir KR, Docherty HM, Drummond R, McGowan NW, Forbes S, Heremans Y, Houbracken I, Ross JA, Forbes SJ, *et al.* Suppression of epithelial-to-mesenchymal transitioning enhances ex vivo reprogramming of human exocrine pancreatic tissue toward functional insulin-producing β -like cells. *Diabetes* 2013 **62** 2821–2833. (<https://doi.org/10.2337/db12-1256>)
- 53 Lima MJ, Muir KR, Docherty HM, McGowan NWA, Forbes S, Heremans Y, Heimberg H, Casey J & Docherty K. Generation of functional beta-like cells from human exocrine pancreas. *PLoS ONE* 2016 **11** e0156204. (<https://doi.org/10.1371/journal.pone.0156204>)
- 54 Lemper M, Leuckx G, Heremans Y, German MS, Heimberg H, Bouwens L & Baeyens L. Reprogramming of human pancreatic exocrine cells to β -like cells. *Cell Death and Differentiation* 2015 **22** 1117–1130. (<https://doi.org/10.1038/cdd.2014.193>)
- 55 Baeyens L, De Breuck S, Lardon J, Mfopou JK, Rooman I & Bouwens L. In vitro generation of insulin-producing beta cells from adult exocrine pancreatic cells. *Diabetologia* 2005 **48** 49–57. (<https://doi.org/10.1007/s00125-004-1606-1>)

- 56 Baeyens L, Lemper M, Leuckx G, De Groef S, Bonfanti P, Stangé G, Shemer R, Nord C, Scheel DW, Pan FC, *et al.* Transient cytokine treatment induces acinar cell reprogramming and regenerates functional beta cell mass in diabetic mice. *Nature Biotechnology* 2013 **32** 76–83. (<https://doi.org/10.1038/nbt.2747>)
- 57 Sasaki S, Miyatsuka T, Matsuoka T, Takahara M, Yamamoto Y, Yasuda T, Kaneto H, Fujitani Y, German MS, Akiyama H, *et al.* Activation of GLP-1 and gastrin signalling induces in vivo reprogramming of pancreatic exocrine cells into beta cells in mice. *Diabetologia* 2015 **58** 2582–2591. (<https://doi.org/10.1007/s00125-015-3728-z>)
- 58 Bonner-Weir S, Toschi E, Inada A, Reitz P, Fonseca SY, Aye T & Sharma A. The pancreatic ductal epithelium serves as a potential pool of progenitor cells. *Pediatric Diabetes* 2004 **5** 16–22. (<https://doi.org/10.1111/j.1399-543X.2004.00075.x>)
- 59 Xu X, D'Hoker J, Stangé G, Bonnè S, De Leu N, Xiao X, Van de Castele M, Mellitzer G, Ling Z, Pipeleers D, *et al.* β Cells can be generated from endogenous progenitors in injured adult mouse pancreas. *Cell* 2008 **132** 197–207. (<https://doi.org/10.1016/j.cell.2007.12.015>)
- 60 Bonner-Weir S, Inada A, Yatoh S, Li W-C, Aye T, Toschi E & Sharma A. Transdifferentiation of pancreatic ductal cells to endocrine β -cells. *Biochemical Society Transactions* 2008 **36** 353–356. (<https://doi.org/10.1042/BST0360353>)
- 61 Corritore E, Dugnani E, Pasquale V, Misawa R, Witkowski P, Lei J, Markmann J, Piemonti L, Sokal EM, Bonner-Weir S, *et al.* β -Cell differentiation of human pancreatic duct-derived cells after *in vitro* expansion. *Cellular Reprogramming* 2014 **16** 456–466. (<https://doi.org/10.1089/cell.2014.0025>)
- 62 Zhang M, Lin Q, Qi T, Wang T, Chen C-C, Riggs AD & Zeng D. Growth factors and medium hyperglycemia induce Sox9+ ductal cell differentiation into β cells in mice with reversal of diabetes. *PNAS* 2016 **113** 650–655. (<https://doi.org/10.1073/pnas.1524200113>)
- 63 Solar M, Cardalda C, Houbracken I, Martín M, Maestro MA, De Medts N, Xu X, Grau V, Heimberg H, Bouwens L, *et al.* Pancreatic exocrine duct cells give rise to insulin-producing β cells during embryogenesis but not after birth. *Developmental Cell* 2009 **17** 849–860. (<https://doi.org/10.1016/j.devcel.2009.11.003>)
- 64 Kopp JL, Dubois CL, Schaffer AE, Hao E, Shih HP, Seymour PA, Ma J & Sander M. Sox9+ ductal cells are multipotent progenitors throughout development but do not produce new endocrine cells in the normal or injured adult pancreas. *Development* 2011 **138** 653–665. (<https://doi.org/10.1242/dev.056499>)
- 65 Kopinke D, Brailsford M, Shea JE, Leavitt R, Scaife CL & Murtaugh LC. Lineage tracing reveals the dynamic contribution of Hes1+ cells to the developing and adult pancreas. *Development* 2011 **138** 431–441. (<https://doi.org/10.1242/dev.053843>)
- 66 Rankin MM, Wilbur CJ, Rak K, Shields EJ, Granger A & Kushner JA. β -Cells are not generated in pancreatic duct ligation-induced injury in adult mice. *Diabetes* 2013 **62** 1634–1645. (<https://doi.org/10.2337/db12-0848>)
- 67 Horb ME, Shen CN, Tosh D & Slack JMW. Experimental conversion of liver to pancreas. *Current Biology* 2003 **13** 105–115. ([https://doi.org/10.1016/S0960-9822\(02\)01434-3](https://doi.org/10.1016/S0960-9822(02)01434-3))
- 68 Meivar-Levy I & Ferber S. Reprogramming of liver cells into insulin-producing cells. *Best Practice and Research: Clinical Endocrinology and Metabolism* 2015 **29** 873–882. (<https://doi.org/10.1016/j.beem.2015.10.006>)
- 69 Ferber S, Halkin A, Cohen H, Ber I, Einav Y, Goldberg I, Barshack I, Seiffers R, Kopolovic J, Kaiser N, *et al.* Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. *Nature Medicine* 2000 **6** 568–572. (<https://doi.org/10.1038/75050>)
- 70 Ber I, Shternhall K, Perl S, Ohanuna Z, Goldberg I, Barshack I, Benvenisti-Zarum L, Meivar-Levy I & Ferber S. Functional, persistent, and extended liver to pancreas transdifferentiation. *Journal of Biological Chemistry* 2003 **278** 31950–31957. (<https://doi.org/10.1074/jbc.M303127200>)
- 71 Berneman-Zeitouni D, Molakandov K, Elgart M, Mor E, Fornoni A, Domínguez MR, Kerr-Conte J, Ott M, Meivar-Levy I & Ferber S. The temporal and hierarchical control of transcription factors-induced liver to pancreas transdifferentiation. *PLoS ONE* 2014 **9** e87812. (<https://doi.org/10.1371/journal.pone.0087812>)
- 72 Wang AY, Ehrhardt A, Xu H & Kay MA. Adenovirus transduction is required for the correction of diabetes using Pdx-1 or neurogenin-3 in the liver. *Molecular Therapy* 2007 **15** 255–263. (<https://doi.org/10.1038/sj.mt.6300032>)
- 73 Yechoor V, Liu V, Paul A, Lee J, Buras E, Ozer K, Samson S & Chan L. Gene therapy with neurogenin 3 and betacellulin reverses major metabolic problems in insulin-deficient diabetic mice. *Endocrinology* 2009 **150** 4863–4873. (<https://doi.org/10.1210/en.2009-0527>)
- 74 Banga A, Akinci E, Greder LV, Dutton JR & Slack JMW. In vivo reprogramming of Sox9+ cells in the liver to insulin-secreting ducts. *PNAS* 2012 **109** 15336–15341. (<https://doi.org/10.1073/pnas.1201701109>)
- 75 Cerdá-Esteban N, Naumann H, Ruzittu S, Mah N, Pongrac IM, Cozzitorto C, Hommel A, Andrade-Navarro MA, Bonifacio E & Spagnoli FM. Stepwise reprogramming of liver cells to a pancreas progenitor state by the transcriptional regulator Tgfb2. *Nature Communications* 2017 **8** 14127. (<https://doi.org/10.1038/ncomms14127>)
- 76 Schonhoff SE, Giel-Moloney M & Leiter AB. Neurogenin 3-expressing progenitor cells in the gastrointestinal tract differentiate into both endocrine and non-endocrine cell types. *Developmental Biology* 2004 **270** 443–454. (<https://doi.org/10.1016/j.ydbio.2004.03.013>)
- 77 Talchai C, Xuan S, Kitamura T, DePinho RA & Accili D. Generation of functional insulin-producing cells in the gut by Foxo1 ablation. *Nature Genetics* 2012 **44** 406–412. (<https://doi.org/10.1038/ng.2215>)
- 78 Bouchri R, Foo KS, Hua H, Tsuchiya K, Ohmura Y, Sandoval PR, Ratner LE, Egli D, Leibel RL & Accili D. FOXO1 inhibition yields functional insulin-producing cells in human gut organoid cultures. *Nature Communications* 2014 **5** 4242. (<https://doi.org/10.1038/ncomms5242>)
- 79 Chen Y-J, Finkbeiner SR, Weinblatt D, Emmett MJ, Tameire F, Yousefi M, Yang C, Maehr R, Zhou Q, Shemer R, *et al.* De novo formation of insulin-producing 'Neo- β cell islets' from intestinal crypts. *Cell Reports* 2014 **6** 1046–1058. (<https://doi.org/10.1016/j.celrep.2014.02.013>)
- 80 Hsu PD, Lander ES & Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. *Cell* 2014 **157** 1262–1278. (<https://doi.org/10.1016/j.cell.2014.05.010>)
- 81 Hilton IB, D'Ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE & Gersbach CA. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. *Nature Biotechnology* 2015 **33** 510–517. (<https://doi.org/10.1038/nbt.3199>)
- 82 Liao H-K, Hatanaka F, Araoka T, Reddy P, Wu MZ, Sui Y, Yamauchi T, Sakurai M, O'Keefe DD, Núñez-Delgado E, *et al.* In vivo target gene activation via CRISPR/Cas9-mediated trans-epigenetic modulation. *Cell* 2017 **171** 1495.e15–1507.e15. (<https://doi.org/10.1016/j.cell.2017.10.025>)
- 83 Bradley A, Evans M, Kaufman MH & Robertson E. Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines. *Nature* 1984 **309** 255–256. (<https://doi.org/10.1038/309255a0>)
- 84 Kobayashi T, Yamaguchi T, Hamanaka S, Kato-Itoh M, Yamazaki Y, Ibata M, Sato H, Lee YS, Usui J, Knisely AS, *et al.* Generation of rat pancreas in mouse by interspecific blastocyst injection of pluripotent stem cells. *Cell* 2010 **142** 787–799. (<https://doi.org/10.1016/j.cell.2010.07.039>)
- 85 Usui J, Kobayashi T, Yamaguchi T, Knisely AS, Nishinakamura R & Nakauchi H. Generation of kidney from pluripotent stem cells via blastocyst complementation. *American Journal of Pathology* 2012 **180** 2417–2426. (<https://doi.org/10.1016/j.ajpath.2012.03.007>)

- 86 Rashid T, Kobayashi T & Nakauchi H. Revisiting the flight of Icarus: making human organs from PSCs with large animal chimeras. *Cell Stem Cell* 2014 **15** 406–409. (<https://doi.org/10.1016/j.stem.2014.09.013>)
- 87 Bourret R, Martinez E, Vialla F, Giquel C, Thonnat-Marin A & De Vos J. Human–animal chimeras: ethical issues about farming chimeric animals bearing human organs. *Stem Cell Research and Therapy* 2016 **7** 87. (<https://doi.org/10.1186/s13287-016-0345-9>)
- 88 James D, Noggle SA, Swigut T & Brivanlou AH. Contribution of human embryonic stem cells to mouse blastocysts. *Developmental Biology* 2006 **295** 90–102. (<https://doi.org/10.1016/j.ydbio.2006.03.026>)
- 89 Gafni O, Weinberger L, Mansour AA, Manor YS, Chomsky E, Ben-Yosef D, Kalma Y, Viukov S, Maza I, Zviran A, *et al.* Derivation of novel human ground state naive pluripotent stem cells. *Nature* 2013 **504** 282–286. (<https://doi.org/10.1038/nature12745>)
- 90 Yamaguchi T, Sato H, Kato-Itoh M, Goto T, Hara H, Sanbo M, Mizuno N, Kobayashi T, Yanagida A, Umino A, *et al.* Interspecies organogenesis generates autologous functional islets. *Nature* 2017 **542** 191–196. (<https://doi.org/10.1038/nature21070>)
- 91 Wu J, Platero-Luengo A, Sakurai M, Sugawara A, Gil MA, Yamauchi T, Suzuki K, Bogliotti YS, Cuello C, Morales Valencia M, *et al.* Interspecies chimerism with mammalian pluripotent stem cells. *Cell* 2017 **168** 473.e15–486.e15. (<https://doi.org/10.1016/j.cell.2016.12.036>)
- 92 Vilarino M, Rashid ST, Suchy FP, McNabb BR, van der Meulen T, Fine EJ, Ahsan S, Mursaliyev N, Sebastiano V, Diab SS, *et al.* CRISPR/Cas9 microinjection in oocytes disables pancreas development in sheep. *Scientific Reports* 2017 **7** 17472. (<https://doi.org/10.1038/s41598-017-17805-0>)

Received in final form 26 February 2018

Accepted 27 February 2018

